Pancreatic Cell News 8.21 May 30, 2017 | |
| |
TOP STORYThe regulation and biological actions of heat shock factor protein 1 (HSF1) in beta cells remain elusive. The authors sought to investigate the regulation of HSF1 in pancreatic beta cells and to study its potential role in cell survival. [Diabetologia] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DIABETES & PANCREATITISThe authors screened small molecules that increased the induction rate of insulin (INS)+ cells from human embryonic stem cell (hESC)-derived pancreatic and duodenal homeobox 1+ pancreatic progenitor cells. The differentiation protocol to generate INS+ cells from hiPSCs/hESCs was optimized using hit compounds, and INS+ cells induced with the compounds were characterized for their in vitro and in vivo functions. [Diabetologia] Abstract ML355 prevented the reduction of insulin secretion and oxygen consumption rate in cytokine treated human islets and improved both parameters in human islets from type 2 diabetes donors. [J Clin Endocrinol Metab] Abstract Regulator of G Protein Signaling 2 Is a Key Regulator of Pancreatic β-Cell Mass and Function Researchers showed that regulator of G protein signaling protein 2 (RGS2)−/− islets secreted more insulin than RGS2+/+ islets when challenged with glucose or exendin-4. RGS2-knockdown cells are susceptible to hypoxia induced cell death while RGS2-overexpressing cells are protected from cell death. [Cell Death Dis] Full Article Investigators demonstrated that glucokinase activation using a glucokinase activator significantly upregulated the expression of Fibulin-5, a matricellular protein involved in matrix-cell signaling, in isolated mouse islets. [Sci Rep] Full Article Scientists demonstrated that MIN6 cells with a specific knockdown of long isoforms of nuclear factor erythroid 2 like 1 (Nfe2l1) by lentiviral shRNA were vulnerable to arsenite-induced apoptosis and cell damage. [Toxicol Appl Pharmacol] Abstract PANCREATIC CANCERThe authors observed differential downregulation of microRNA (miR)-205 in human pancreatic cancer tissues and cells. Compared to gemcitabine (GEM)-sensitive MIA PaCa-2 cells, miR-205 was highly downregulated in GEM-resistant MIA PaCa-2R cells. [Cancer Lett] Abstract Investigators found that curcumin inhibited cell proliferation and triggered cell cycle arrest and apoptosis in pancreatic cancer, which is associated with increased expression of PTEN and p73. [Biochem Pharmacol] Abstract | Graphical Abstract The identification of a novel peroxisome proliferator-activated receptor (PPAR) antagonist, showing inhibitory activity on PPARα and a weaker antagonism on PPARγ, is described. The activity of this compound and of a series of chemical analogues was investigated in selected tumor cell lines, expressing both PPARα and PPARγ. [Chem Biol Drug Des] Abstract Investigators analyzed long intergenic non-coding RNA, regulator of reprogramming (linc-ROR) expression in pancreatic ductal adenocarcinoma and determined the regulation effects of linc-ROR on proliferation and invasion of cancer cells, as well as properties of cancer stem-like cells. [Cell Death Discov] Full Article | |
| |
REVIEWSEmerging Roles of the CXCL12/CXCR4 Axis in Pancreatic Cancer Progression and Therapy Recent exploration of combination therapies with CXCR4 antagonists have demonstrated improved outcomes, and abolishing the contribution of this pathway may prove crucial to effectively treat pancreatic cancer at both the primary tumor and metastases. [Pharmacol Ther] Abstract Visit our reviews page to see a complete list of reviews in the pancreatic cell research field. | |
| |
SCIENCE NEWSMabVax Therapeutics Holdings, Inc. announced that results from the Phase I clinical trial of MabVax’s therapeutic antibody MVT-5873, being evaluated in advanced pancreatic cancer and other CA19-9 positive cancers, will be presented in a poster presentation. [Press release from MabVax Therapeutics Holdings, Inc. discussing research to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago] Press Release Poxel Presents Imeglimin Japanese Phase I Results and Mechanistic Data Poxel SA announced the presentation of a comprehensive summary of the Phase I data of Imeglimin in Japanese subjects and additional preclinical mechanistic data on Imeglimin’s unique mechanism of action in insulin secretion in response to glucose. [Press release from Poxel SA discussing research to be presented at the 9th Scientific Meeting of the Asian Association for the Study of Diabetes (AASD), Nagoya] Press Release Adocia Announces Six Data Presentations Adocia announced that six abstracts supporting the application of its proprietary BioChaperone® technology for the development of innovative diabetes treatments have been accepted for poster presentation. [Press release from Adocia discussing research to be presented at the American Diabetes Association 77th Scientific Sessions, San Diego] Press Release | |
| |
INDUSTRY NEWSCalciMedica, Inc., announced that it received Fast-Track designation from the U.S. Food and Drug Administration for its lead clinical compound, CM4620, a novel, calcium release-activated calcium (CRAC) channel inhibitor, for the treatment of acute pancreatitis. [CalciMedica, Inc.] Press Release PCI Biotech and RXi Pharmaceuticals Extend Research Collaboration to the Field of Immuno-Oncology PCI Biotech and RXi Pharmaceuticals announced that they are extending their preclinical research collaboration initiated April 7, 2015. [PCI Biotech] Press Release | |
| |
POLICY NEWSTexas on Track to Become First State to Explicitly Back Stem Cell Therapies Lawmakers in Austin have approved a bill authorizing unapproved stem cell therapies, putting Texas on track to become the first state to explicitly recognize the experimental treatments. [STAT News] Editorial NIH Scales Back Plan to Curb Support for Big Labs after Hearing Concerns Faced with a barrage of criticism, the National Institutes of Health (NIH) has scaled back a plan to cap its support for individual labs in order to free up funds for more scientists. The changes did not appease scientists who gave NIH a tongue-lashing at a meeting of NIH’s Council of Councils. [ScienceInsider] Editorial House Science Panel Joins Trump in Questioning Research Overhead Payments A hearing on how the U.S. government defrays the cost of doing federally funded research on college campuses might put most people to sleep. But when budgets are tight, the billions of dollars being spent each year on so-called overhead become an irresistible target for lawmakers. [ScienceInsider] Editorial
| |
EVENTSNEW Drug Discovery & Therapy World Congress 2017 Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW PhD Position – Health/Biomedical Sciences (University of Auckland) Postdoctoral Position – Metabolic Regulation of Embryonic and Stem Cells (Joslin Diabetes Center) Postdoctoral Fellowship – Diabetes UK (Diabetes UK) PhD Studentship – Diabetes UK (Diabetes UK) Research Leaders – Career Development Award or Tenure Track (Medical Research Council) Postdoctoral Fellow – Diabetes (University of Toronto) Postdoctoral Associate – Pancreatic Beta Cells (Johns Hopkins School of Medicine) Faculty Member – Endocrinology, Diabetes and Metabolism (Johns Hopkins University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|